Harvard Bioscience

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. It operates under the geographical segments: United States, Germany, United Kingdom, and Rest of the world. It sells its products through catalog, Website, distributors, and direct sales force. The company was founded by Dr. William T. Porter in 1901 and is headquartered in Holliston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Harvard Bioscience reports strong Q4 earnings, eyes China growth

Harvard Bioscience delivered solid financial performance in Q4 2022 with revenue growth and strong margins.
The company faces challenges in supply chain issues and debt reduction but is focused on growth opportunities.
Strategic plans for new product development and improving gross margins are key priorities for future success.

Harvard Bioscience reports strong Q1 earnings, eyes growth opportunities

Harvard Bioscience delivered solid Q1 2023 results with revenue growth, improved margins, and enhanced profitability. While facing challenges in sales organization and market shifts, the company is strategically positioned to capitalize on opportunities for growth through new product offerings and operational efficiencies.

Harvard Bioscience reports mixed Q2 results, eyes growth opportunities

Harvard Bioscience's Q2 2023 performance showed slight revenue decline but notable improvements in margins and profitability.
The company's strengths include new product launches, positive financial metrics, and a promising revenue guidance for 2023.
Challenges include managing discontinued products impact, sales force effectiveness, and profitability.
Opportunities exist in leveraging new products, addressing challenges, and optimizing financial performance drivers.

Harvard Bioscience reports improved margins and profitability in Q3

Harvard Bioscience (HBIO) showed mixed performance in Q3 2023 with revenue decline but improved margins and profitability. The company aims to sustain growth through new product launches and service expansion while managing debt effectively.

Harvard Bioscience reports Q4 results, eyes growth through new products

Harvard Bioscience reported mixed Q4 2023 results with revenue decline in some regions.
The company aims for long-term growth through new products and market expansion.
Challenges include revenue decline in certain regions and maintaining/improving margins.
Opportunities lie in new product launches, partnerships, and market expansion strategies.

Harvard Bioscience faces Q1 revenue dip, eyes second-half turnaround

Harvard Bioscience navigated a tough Q1 marked by revenue declines in key regions and operational challenges. However, the company's focus on new product launches and efficiency in maintaining a strong gross margin are positive indicators. Looking ahead, Harvard Bioscience anticipates a turnaround in the second half of the year with improved margins and overall performance.

Harvard Bioscience reports Q3 revenue decline, eyes growth opportunities

Harvard Bioscience faced revenue decline in Q3 due to China and Asia Pacific weakness but expects stabilization and growth.
Operational improvements and cost reductions are enhancing efficiency and profitability.
New product launches and focus on high-growth areas position the company for incremental growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Harvard Bioscience, Inc. (NASDAQ:HBIO ) Q3 2024 Results Conference Call November 7, 2024 8:00 AM ET Company Participants Kathryn Flynn - Corporate Controller James Green - Chairman, President and CEO Jennifer Cote - CFO Conference Call Participants Paul Knight - KeyBanc Bruce Jackson - The Benchmark Company Operator Good day, and welcome to the Third Quarter 2024 Harvard Biosciences Inc. Earnings Conference Call. [Operator Instructions] As a reminder, this call may be recorded.

Harvard Bioscience, Inc. (HBIO) Q3 2024 Earnings Call Transcript

HOLLISTON, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2024 before the market opens on November 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

Harvard Bioscience Schedules Third Quarter 2024 Earnings Conference Call for November 7, 2024 at 8:00 AM ET

Mettler-Toledo

The Zacks Instruments - Scientific industry participants like MTD and HBIO are gaining from strong life science, pharmaceutical and academic end-market demand despite the challenging macroeconomic environment.

2 Instruments Stocks to Watch From a Challenging Industry

Solutions for CROs, pharma and biotechs streamline testing and enable fundamental advancements in preclinical and organoid focused therapy development Solutions for CROs, pharma and biotechs streamline testing and enable fundamental advancements in preclinical and organoid focused therapy development

Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Safety Pharmacology Society Annual Meeting

HOLLISTON, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be participating in the Sidoti Small Cap Virtual Conference on September 18th, 2024, with a presentation time of 9:15 am ET.

Harvard Bioscience, Inc. to Participate in the Sidoti Small Cap Virtual Conference

Harvard Bioscience, Inc. (NASDAQ:HBIO ) Q2 2024 Earnings Conference Call August 8, 2024 10:00 AM ET Company Participants Kathryn Flynn - Corporate Controller James Green - Chairman, President and CEO Jennifer Cote - CFO Conference Call Participants Paul Knight - KeyBanc Capital Markets Bruce Jackson - The Benchmark Company Christopher Sakai - Singular Research Operator Good day, and thank you for standing by. Welcome to the Q2 2024 Harvard Bioscience, Inc. Earnings Conference Call.

Harvard Bioscience, Inc. (HBIO) Q2 2024 Earnings Call Transcript

HOLLISTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the second quarter ended June 30, 2024.

Harvard Bioscience Announces Second Quarter 2024 Financial Results

HOLLISTON, Mass., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended June 30, 2024 before the market opens on August 8, 2024, and will hold a conference call to discuss the results at 10:00 a.m. Eastern Time.

Harvard Bioscience Schedules Second Quarter 2024 Earnings Conference Call for August 8, 2024 at 10:00 AM ET

HOLLISTON, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be presenting to investors at the 14th Annual East Coast IDEAS Conference at the Jay Conference Center – Bryant Park in New York City on June 12, 2024.

Harvard Bioscience, Inc. to Present and Host One-on-One Meetings at the 14th Annual East Coast IDEAS Conference on June 12, 2024

HOLLISTON, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be presenting to investors at the Jefferies Global Healthcare Conference at the Marriott Marquis in New York City on June 5, 2024.

Harvard Bioscience, Inc. to Present at the Jefferies Global Healthcare Conference on June 5, 2024

HOLLISTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be participating in the Benchmark Healthcare House Call Virtual Conference on May 22nd, 2024, with a live fireside chat scheduled for 9:00-9:40 am ET. The Company will also be hosting one-on-one meetings with investors in conjunction with the Conference.

Harvard Bioscience, Inc. to Participate in the Benchmark Healthcare House Call Virtual Conference

Harvard Bioscience, Inc. (NASDAQ:HBIO ) Q1 2024 Earnings Conference Call May 7, 2024 8:00 AM ET Company Participants Dave Sirois - Director, SEC Reporting Jim Green - Chairman, President and CEO Jennifer Cote - CFO Conference Call Participants Paul Knight - KeyBanc Bruce Jackson - The Benchmark Company Frank DiLorenzo - Singular Research Operator Good day, and thank you for standing by. Welcome to the Q1 2024 Harvard Bioscience Inc. Earnings Conference Call.

Harvard Bioscience, Inc. (HBIO) Q1 2024 Earnings Call Transcript

Harvard Bioscience (HBIO) came out with quarterly earnings of $0.02 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.06 per share a year ago.

Harvard Bioscience (HBIO) Q1 Earnings Match Estimates

Strong gross margin performance and focus on efficiency to support ongoing investments in growth Strong gross margin performance and focus on efficiency to support ongoing investments in growth

Harvard Bioscience Announces First Quarter 2024 Financial Results

HOLLISTON, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2024 before the market opens on May 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

Harvard Bioscience Schedules First Quarter 2024 Earnings Conference Call for May 7, 2024 at 8:00 AM ET

AudioEye Inc

Manhattan Associates

MSCI

Texas Instruments

Here is a sneak peek into how five technology stocks, MANH, MSCI, AEYE, HBIO and TXN, are expected to fare in their quarterly results slated to be released on Apr 23.

Watch These 5 Technology Stocks for Q1 Earnings: Beat or Miss?

HOLLISTON, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced a labor force reduction to improve its operating cost structure and support its ongoing investments in growth.

Harvard Bioscience Announces Action to Improve Operational Efficiency and Support Ongoing Investments in Growth

HOLLISTON, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, will be presenting to investors at the upcoming Sidoti Small Cap Conference and KeyBanc Life Sciences & MedTech Conference, both to be held virtually in March 2024. Joining him will be Jennifer Cote, the Company's Chief Financial Officer.

Harvard Bioscience, Inc. to Participate in March 2024 Investor Conferences: Sidoti's Small Cap Conference and KeyBanc's Life Sciences & MedTech Conference

Harvard Bioscience, Inc. (NASDAQ:HBIO ) Q4 2023 Earnings Conference Call March 7, 2024 8:00 AM ET Company Participants Dave Sirois - Director, SEC Reporting Jim Green - Chairman, President & Chief Executive Officer Jennifer Cote - Chief Financial Officer Conference Call Participants Paul Knight - KeyBanc Frank DiLorenzo - Singular Research Operator Good morning, and thank you for standing by. Welcome to Harvard Bioscience, Inc. Fourth Quarter 2023 Earnings Conference Call.

Harvard Bioscience, Inc. (HBIO) Q4 2023 Earnings Call Transcript

HOLLISTON, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the fourth quarter and year ended December 31, 2023.

Harvard Bioscience Announces Fourth Quarter 2023 Financial Results

Solutions for CROs, pharma and biotechs improve throughput and efficiency and enable future advancements in data analytics Solutions for CROs, pharma and biotechs improve throughput and efficiency and enable future advancements in data analytics

Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Society of Toxicology Meeting

HOLLISTON, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2023 before the market opens on March 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

Harvard Bioscience Schedules Fourth Quarter 2023 Earnings Conference Call for March 7, 2024 at 8:00 AM ET

HOLLISTON, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced it will be presenting at the Benchmark Company 12th Annual Discovery One-on-One Investor Conference to be held Thursday December 7th, 2023 at the New York Athletic Club in New York City.

Harvard Bioscience to Present at Benchmark Company's Discovery One-On-One Investor Conference on December 7, 2023

HOLLISTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer Jim Green will present to investors at the Southwest IDEAS Investor Conference on Thursday November 16, 2023 at The Statler in Dallas, Texas. Joining him will be Jennifer Cote, the company's Chief Financial Officer and Treasurer.

Harvard Bioscience to Present at Southwest IDEAS Investor Conference on November 16, 2023

Harvard Bioscience, Inc. (NASDAQ:HBIO ) Q3 2023 Earnings Conference Call November 7, 2023 8:00 AM ET Company Participants Dave Sirois - Director, Corporate Accounting & SEC Reporting James Green - Chairman, President & Chief Executive Officer Jennifer Cote - Chief Financial Officer Conference Call Participants Bruce Jackson - The Benchmark Company Operator Thank you for standing by and welcome to the Harvard Biosciences Third Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, today's program is being recorded.

News for Harvard Bioscience Stock (HBIO)